10x Genomics Inc. (TXG) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for 10x Genomics Inc. (TXG) stock, showing its current price and daily performance. It notes the absence of analyst ratings and earnings information for the company. The page also features an advertisement for a virtual trading conference and free trade alerts.
10x Genomics Seen As Key Player In AI-Driven Biological Data Buildout
William Blair upgraded 10x Genomics Inc. (NASDAQ: TXG) citing its strong technology and position to benefit from recovering markets and demand for large-scale biological datasets to train AI models. The upgrade is also supported by improving execution and profitability trends, including stabilized single-cell performance and strong fourth-quarter sales. While AI-related revenue is currently small, it is expected to become an important growth area as demand for high-quality biological datasets accelerates.
Vanguard realigns reporting; subsidiaries to report TXG holdings (TXG)
Vanguard's recent Schedule 13G/A amendment for 10X Genomics (TXG) indicates that The Vanguard Group now reports zero beneficial ownership of TXG shares. This change is due to an internal realignment effective January 12, 2026, where Vanguard's subsidiaries will now report their holdings separately, as permitted by SEC Release No. 34-39538. This filing represents an administrative adjustment in reporting structure rather than an economic divestiture, and investors are advised to expect separate filings from Vanguard affiliates.
10x genomics CEO Saxonov sells $288,908 in stock By Investing.com
Serge Saxonov, CEO of 10x Genomics, Inc. (NASDAQ:TXG), sold 15,000 shares of Class A Common Stock for a total of $288,908. These sales occurred on March 23 and 24, 2026, under a pre-arranged Rule 10b5-1 trading plan, following a significant surge in the company's stock price. The transactions leave Saxonov with 1,172,273 directly owned shares and come amidst other company developments, including a new spatial biology initiative and analyst price target increases, though ARK Invest has reduced its holdings.
10x genomics CEO Saxonov sells $288,908 in stock
Serge Saxonov, CEO of 10x Genomics (NASDAQ:TXG), sold 15,000 shares of Class A Common Stock for a total of $288,908 on March 23 and 24, 2026. These transactions, executed under a pre-arranged trading plan, occurred as TXG shares have significantly risen. The company has also been involved in new initiatives like the STELA project and received increased price targets from analysts, despite ARK Invest selling shares and concerns about a new AI model.
10x Genomics (NASDAQ: TXG) CEO sells 15,000 shares under Rule 10b5-1 plan
10x Genomics, Inc. CEO Serge Saxonov sold a total of 15,000 shares of Class A Common Stock over two days, March 23 and March 24, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales were executed at weighted average prices of $19.1297 and $19.5223 per share, respectively. Following these transactions, Saxonov directly holds 1,172,273 Class A shares, along with significant indirect and Class B holdings through various trusts.
10x genomics CEO Saxonov sells $288,908 in stock
Serge Saxonov, CEO of 10x Genomics, Inc. (NASDAQ:TXG), sold 15,000 shares of Class A Common Stock for a total of $288,908 on March 23 and 24, 2026. These transactions, executed under a pre-arranged trading plan, occurred after significant stock gains for TXG. The company is also involved in several key developments, including a large-scale spatial biology initiative and price target raises from multiple analysts, alongside some institutional selling and concerns about new AI models.
Vanguard amends 13G for 10X Genomics (NASDAQ: TXG) reporting 0 shares
Vanguard has filed an amendment to its Schedule 13G for 10x Genomics (NASDAQ: TXG), reporting beneficial ownership of 0 shares, representing 0% of the class. The filing clarifies that while Vanguard and its managed accounts have rights to dividends or sale proceeds, they do not hold a greater than 5% interest in the company. This amendment updates Vanguard's position as a passive investor, indicating no sole or shared voting or dispositive power over TXG shares.
10x Genomics Stock Analysis: Recent Gains vs. Long-Term Growth Challenges | 2026 - News and Statistics
10x Genomics stock has significantly risen by 39.8% in the past six months, reaching $18.24 per share, attributed partly to strong quarterly performance. However, concerns persist regarding its long-term growth, marked by a demand slowdown, only 1.9% annualized revenue growth over two years, and a negative five-year average return on invested capital of -44.5%. Analysts suggest that despite recent gains, the company's valuation reflects expected unprofitability in the near term, with potential downside risk outweighing upside opportunities.
10x Genomics Down Nearly 12%, on Pace for Largest Percent Decrease Since February 2025 -- Data Talk
10x Genomics (TXG) stock is down significantly by nearly 12%, marking its largest single-day percentage decrease since February 2025. This downturn is attributed to an unfavorable ruling from the European Patent Office.
10x Genomics Inc Class A Trade Ideas — LSX:A2PPQJ
This article compiles various trade ideas and technical analyses for 10x Genomics Inc Class A (LSX:A2PPQJ, NASDAQ:TXG). Contributors discuss wave counts, fib levels, cup and handle patterns, ABC patterns, and indicator signals like Aroon and MACD for potential long and short positions. The company profile highlights 10x Genomics' role in developing instruments and software for biological analysis, serving academic, government, and biotechnology institutions.
AAKG ETF Holdings List — XETR:AAKG
This article lists the current holdings of the Ark Genomic Revolution UCITS ETF (AAKG) as of March 17, 2026. It provides a detailed breakdown of the top holdings, including company symbols, weight percentages, number of shares, and market values for each company. The ETF has significant investments in companies like Twist Bioscience Corp., CRISPR Therapeutics AG, and Tempus AI, Inc.
10x genomics CEO Saxonov sells $367,096 in shares
Serge Saxonov, CEO of 10x Genomics Inc, sold 16,152 shares of Class A Common Stock for approximately $367,096 on March 2, 2026, and an additional 2,750 shares on March 3, 2026. These sales occurred as the stock traded near its 52-week high after a significant 105% gain over the past year. The company recently reported strong Q4 2025 earnings, leading analysts like Stifel and Canaccord Genuity to raise their price targets.
FMR LLC owns 18.54M shares of 10x Genomics (NASDAQ: TXG) in 13G/A
FMR LLC has filed a Schedule 13G/A report indicating beneficial ownership of 18,543,561.62 Class A common shares of 10x Genomics (NASDAQ: TXG), representing 15.6% of the class as of February 27, 2026. This figure includes 892,772 Class B shares held by Fidelity-advised funds which are convertible to Class A shares on a 1:1 basis. Abigail P. Johnson is also listed with shared reporting authority over the same position.
10x genomics CEO Saxonov sells $367,096 in shares
Serge Saxonov, CEO of 10x Genomics Inc (NASDAQ:TXG), sold 16,152 shares of Class A Common Stock for approximately $367,096 on March 2, 2026, and an additional 2,750 shares on March 3, 2026, valued at $0, coinciding with the stock trading near its 52-week high after a 105% gain over the past year. Following these transactions, Saxonov still holds over 1.2 million directly owned shares and additional shares in various trusts. The recent sales occurred shortly after 10X Genomics reported strong Q4 2025 earnings, surpassing expectations, and subsequently received raised price targets and reaffirmed "Buy" ratings from Stifel and Canaccord Genuity, driven by the strong adoption of their Flex Apex product.
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Ascendis Pharma (ASND) and Roche Holding AG (OtherRHHVF)
Healthcare analysts have provided new ratings for 10x Genomics (TXG), Ascendis Pharma (ASND), and Roche Holding AG (RHHVF). Stifel Nicolaus maintained a Buy rating on 10x Genomics with a $25.00 price target, while also reiterating a Buy on Ascendis Pharma with a $325.00 price target. J.P. Morgan maintained a Hold rating on Roche Holding AG with a CHF350.00 price target.
10x Genomics (TXG) CEO sells shares and makes stock gift
10x Genomics CEO Serge Saxonov reported selling 16,152 shares of Class A common stock and making a gift of 2,750 shares, according to a recent SEC Form 4 filing. The share sales occurred on March 2, 2026, under a Rule 10b5-1 trading plan, at weighted average prices of $22.6690 and $23.1781. Following these transactions, Saxonov directly holds over 1.2 million shares and also has indirect holdings through several trusts for which he serves as trustee.
10x Genomics (TXG) CFO granted 106,579 RSUs in new equity award
10x Genomics CFO Adam Taich has been granted 106,579 Restricted Stock Units (RSUs) in a new equity award, as reported in a recent SEC Form 4 filing. This award, given at no cash cost, increases his directly held beneficial ownership to 394,996 shares. The RSUs are designed for retention and performance alignment, vesting quarterly over time, with the first installment on February 21, 2026.
88,816 RSUs awarded to 10x Genomics (TXG) director Hindson
Benjamin J. Hindson, a director and officer of 10x Genomics, Inc. (TXG), was granted 88,816 restricted stock units (RSUs) as reported in a recent Form 4 SEC filing. These RSUs, valued at $0.00 per share, will vest quarterly starting February 21, 2026, provided Hindson remains a service provider. After this grant, his total directly held Class A Common Stock, including RSUs, amounts to 513,595 shares.
Major RSU grant to 10x Genomics (TXG) CEO Serge Saxonov
10x Genomics CEO Serge Saxonov received a grant of 157,895 Restricted Stock Units (RSUs) on February 26, 2026. These RSUs, which represent Class A Common Stock, vest quarterly over three years, contingent on his continued employment. The SEC filing also details Saxonov's indirect holdings through various trusts for which he serves as trustee.
TXG affiliate files Form 144: proposed Class A Common sale (NASDAQ: TXG)
An affiliate of 10x Genomics, Inc. (NASDAQ: TXG) has filed a Form 144, proposing to sell Class A Common stock. The filing details several vested RSU lots, including quantities of 16,152, 4,879, 3,265, 3,723, 8,156, and 4,977 shares, which are tied to issuer vesting events. JP Morgan Securities LLC is listed as the broker for these transactions on the Nasdaq market.
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Ascendis Pharma (ASND) and Roche Holding AG (OtherRHHVF)
Analysts have provided new ratings for several healthcare companies. Stifel Nicolaus maintained a Buy rating on 10x Genomics (TXG) with a $25.00 price target and reiterated a Buy rating on Ascendis Pharma (ASND) with a $325.00 price target. J.P. Morgan maintained a Hold rating on Roche Holding AG (RHHVF) with a CHF350.00 price target.
Director at 10x Genomics (TXG) sells 7,579 shares under 10b5-1 plan
Sarah A. Teichmann, a director at 10x Genomics (TXG), sold 7,579 shares of Class A Common Stock at $19.41 per share. The transaction, conducted under a pre-arranged Rule 10b5-1 trading plan, leaves her with 26,780 directly held shares. The filing indicates a moderate impact and negative sentiment on the stock.
10x Genomics (TXG) CEO sells 9,632 shares to cover RSU tax
Serge Saxonov, CEO of 10x Genomics (TXG), reported the sale of 9,632 Class A common shares on February 23, 2026, at an average price of $18.5764 per share. This transaction was executed to fulfill tax withholding obligations tied to the vesting of restricted stock units (RSUs). After the sale, Mr. Saxonov directly holds 1,061,924 Class A shares and maintains indirect holdings through various trusts.
[Form 4] 10x Genomics, Inc. Insider Trading Activity
10x Genomics, Inc.'s Chief Financial Officer, Adam Taich, reported an open-market sale of 8,968 Class A Common Stock shares on February 23, 2026, at an average price of $18.5764 per share. This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units. Following the sale, Mr. Taich directly owns 288,417 shares of the company's Class A Common Stock.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG)
Analysts have issued mixed ratings for two healthcare stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG). A Maxim Group analyst maintained a Hold rating on Vertex Pharmaceuticals, while the overall consensus for VRTX is a Strong Buy. For 10x Genomics, a Jefferies analyst reiterated a Buy rating, aligning with a Moderate Buy consensus from other analysts.
10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference
10x Genomics, Inc. (Nasdaq: TXG) announced its management team will participate in a fireside chat at the 46th Annual TD Cowen Health Care Conference. The event is scheduled for Tuesday, March 3, at 11:50 a.m. Eastern Time. Further details are available on prnewswire.com.
Hardman & Co Healthcare Index: 2023 – Capital demands dent performance
The Hardman & Co Healthcare Index (HHI) fell 3.7% in 2023, underperforming major London markets due to the capital-intensive nature of the life sciences sector. Despite challenges in raising capital, 15 companies in the index secured new funding, and 2024 is projected to be busy as more companies will require capital to satisfy auditors. The index, running since 2009, aims to highlight the long-term attractiveness of life sciences investments.
10x Genomics (NASDAQ: TXG) narrows 2025 losses and guides to modest 2026 growth
10x Genomics reported significantly narrowed losses in 2025, driven by improved profitability and reduced operating expenses, despite only modest revenue growth. The company also provided cautious revenue guidance for 2026, projecting 0% to 4% growth when excluding one-time patent litigation settlement revenue from 2025. This financial update highlights a strategic shift towards profitability amidst a challenging market, supported by strong cash reserves and strategic partnerships.
10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026
10x Genomics (Nasdaq: TXG) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a 1% increase in Q4 2025 revenue to $166.0 million and full-year revenue of $642.8 million, or $598.7 million excluding patent litigation settlements, which represents a 2% decrease year-over-year. For 2026, 10x Genomics forecasts revenue between $600 million and $625 million, demonstrating 0% to 4% growth excluding 2025's non-recurring revenue.
10x Genomics Earnings Preview: Revenue Forecast, Analyst Estimates & Stock Outlook - News and Statistics
10x Genomics is set to release its Q4 2025 earnings report this Thursday, with analysts forecasting a revenue of $159.2 million and an adjusted loss per share of $0.04. The company previously beat revenue and EPS estimates in the last quarter, though its stock has recently declined by 4.5%. The broader life sciences tools and services sector has also underperformed, while discussions about tariffs and corporate tax changes add to economic uncertainty.
UK project turns decades of NHS cancer samples into AI-ready data
10x Genomics has partnered with PharosAI, a UK consortium, in an £18.9 million initiative to convert thousands of archived NHS cancer samples into one of the world's largest multimodal datasets. This project aims to create AI-ready genomic, transcriptomic, imaging, and spatial biology data to accelerate cancer diagnosis, precision therapies, and drug discovery. The program, backed by the UK Research Ventures Catalyst and running through 2027, will democratize secure access to these datasets for researchers globally.
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
PharosAI, a research consortium backed by £18.9 million from the UK Government, is partnering with 10x Genomics to create one of the world's most comprehensive multimodal cancer datasets. They will use 10x Genomics' Xenium spatial platform to analyze archived NHS cancer samples and build advanced AI models for earlier diagnosis, precision therapies, and new treatment discovery, initially focusing on breast cancer. The initiative aims to democratize access to these AI-ready datasets for researchers and innovators globally.
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
PharosAI, a research consortium backed by £18.9 million from the UK Government and other partners, is partnering with 10x Genomics to create one of the world's most comprehensive multimodal cancer datasets using AI and spatial biology. The initiative will leverage 10x Genomics' Xenium spatial platform to transform archived NHS cancer samples into high-resolution datasets, which will be paired with advanced AI models to accelerate earlier diagnosis, enable precision therapies, and speed the discovery of new treatments, starting with breast cancer. This collaboration aims to democratize access to these datasets, positioning the UK at the forefront of AI-driven cancer research.
New study tracks blood signals to guide care for autoimmune disease patients
10x Genomics (NASDAQ: TXG) has announced a collaboration with Brigham & Women's Hospital to launch a blood-based, single-cell study on autoimmune diseases, enrolling 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. The study aims to identify immune signatures linked to disease activity, flare, remission, and treatment response to develop a framework for future clinical reports. This initiative is part of 10x Genomics' multi-year strategy to advance research in blood-based diagnostics and potentially establish a CLIA-certified laboratory for clinical applications.
Sumitomo Mitsui Trust Group Inc. Sells 636,744 Shares of 10x Genomics $TXG
Sumitomo Mitsui Trust Group Inc. reduced its stake in 10x Genomics (NASDAQ:TXG) by 10.6% in the third quarter, selling 636,744 shares and retaining ownership of 5,381,219 shares valued at approximately $62.9 million. The article also notes recent insider sales by Benjamin J. Hindson and CEO Serge Saxonov, and that the company reported Q3 revenue of $149 million with an EPS of -$0.22, beating estimates. Analyst consensus for 10x Genomics is currently "Hold" with an average target price of $16.30.
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease
10x Genomics has partnered with Brigham & Women's Hospital to conduct a study aimed at identifying single-cell immune signatures in patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. This collaboration seeks to develop blood-based diagnostic tools to better understand disease activity, flare, remission, and treatment response in autoimmune diseases. The ultimate goal is to enable personalized medicine in rheumatology by integrating single-cell genomics into clinical workflows and constructing a framework for future clinical reporting.
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease
10x Genomics (Nasdaq: TXG) has announced a collaboration with Brigham & Women's Hospital to conduct a study aimed at advancing blood-based diagnostics for autoimmune diseases. The research will analyze peripheral blood samples from 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis using single-cell profiling to identify immune signatures associated with disease activity and treatment response. This initiative seeks to provide clinicians with better tools for diagnosing and managing complex autoimmune conditions and support personalized medicine in rheumatology.
New research map aims to explain why some organ transplants fail
CareDx and 10x Genomics are collaborating on the ImmuneScape™ program, a multiomics research initiative to understand organ transplant rejection and drug response. This program will use advanced single cell and spatial biology technologies to create high-resolution maps of immune mechanisms involved in rejection. The goal is to generate insights that could lead to new clinical diagnostics and personalized transplant medicine, ultimately improving outcomes for transplant patients.
10x Genomics (TXG) Gains as Analysts Raise Price Targets in Early 2026 - News and Statistics
Shares of 10x Genomics (NASDAQ:TXG) rose by 2.5% on January 2, 2026, following several analyst price target increases, including Barclays, BofA, and Canaccord Genuity. Analysts cited factors like recovering end markets and fading headwinds for their increased optimism. Despite the initial gain, the shares settled to a 0.7% rise, indicating the market viewed the news as meaningful but not fundamentally transformative for the volatile stock.
10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference
10x Genomics, Inc. announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 8:15 a.m. Pacific Time. The company is a leader in single cell and spatial biology. This presentation will offer insights into the company's developments and future outlook.
10x Genomics (Nasdaq: TXG) Xenium Powers ASTRA Atlas of 2,000 Asia-Pacific Tumor Samples
10x Genomics, alongside the Garvan Institute and the University of Tokyo, launched the Asia-Pacific Spatial Translational Research Alliance (ASTRA) on November 18, 2025. This consortium aims to create a pan-cancer spatial atlas of 2,000 tumor samples using 10x Genomics' Xenium platform, focusing on ten major cancer types. ASTRA will establish regional hubs and a shared digital infrastructure to harmonize biospecimens and data, advancing precision oncology across the Asia-Pacific region.
10x Genomics Announces Chief Legal Officer Retirement
10x Genomics announced that its Chief Legal Officer, Eric S. Whitaker, will retire on January 1, 2026, after over eight years of service, transitioning to Strategic Counsel. Dr. Randy Wu will succeed him as General Counsel and Secretary. The company's stock (TXG) currently holds a "Hold" analyst rating with an $18 price target, and Spark’s AI Analyst describes TXG as Neutral, citing strong technical performance but weak financial results.
TXG announces CLO retirement; Randy Wu to serve as General Counsel
10x Genomics (TXG) announced a planned legal leadership transition with Eric S. Whitaker retiring as Chief Legal Officer on January 1, 2026, after over eight years of service. He will transition to Strategic Counsel. Dr. Randy Wu, currently VP of Intellectual Property and Litigation, will succeed Whitaker as General Counsel and Secretary, also effective January 1, 2026.
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium
The Asia-Pacific Spatial Translational Research Alliance (ASTRA) has been formed by researchers from the Garvan Institute of Medical Research in Australia and the University of Tokyo in Japan. This consortium, supported by 10x Genomics' Xenium platform, aims to create a comprehensive pan-cancer spatial atlas by mapping cancer and immune cell interactions across 2,000 tumor samples. The initiative seeks to advance precision oncology in the Asia-Pacific region by providing a shared foundation that integrates molecular and spatial data, addressing the current underrepresentation of these insights in global cancer data.
10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research
10x Genomics has launched the next generation of its Chromium Flex assay, featuring automation-compatible plate-based multiplexing that enables highly scalable and cost-effective single cell analysis. This new assay allows researchers to profile up to 384 samples and 100 million cells per week, expanding the scope of single cell studies to previously unachievable scales and applications. The technology aims to accelerate drug discovery and translational research by providing more data at a lower cost, addressing the growing need for high-quality biological data in AI-driven approaches.
10X Genomics (NASDAQ:TXG) Surges 13% on Q3 Revenue Beat and Strong Guidance
10X Genomics (NASDAQ:TXG) saw its shares surge over 13% after reporting a mixed third quarter for 2025. The company beat analyst expectations for revenue and non-GAAP EPS, reporting $149 million in revenue against an estimated $143.9 million, and a loss of $0.22 per share compared to an estimated loss of $0.29. The positive market reaction was also driven by strong forward guidance for Q4 2025, with a midpoint revenue forecast of $156 million, exceeding analyst expectations of $150.7 million.
10x genomics CEO Serge Saxonov sells $84,393 in stock
Serge Saxonov, CEO of 10x Genomics, sold 7,942 shares of the company's Class A common stock for approximately $84,393 under a Rule 10b5-1 trading plan. Despite TXG shares experiencing a 76% drop over the past year, Saxonov also exercised options to acquire 50,000 shares. The company reported strong Q4 2024 revenue but missed EPS forecasts, and secured a permanent injunction against Parse Biosciences for patent infringement.
Earnings call transcript: 10X Genomics Q2 2025 beats EPS expectations
10X Genomics (NASDAQ: TXG) reported strong Q2 2025 results, beating EPS expectations with $0.28 against a forecast of -$0.37, and revenue reaching $173 million, exceeding estimates by 24.03%. Despite positive financial performance and a turn to net income, the stock fell 2.92% in after-hours trading due to market caution and an uncertain funding environment. The company highlighted growth in consumables, particularly Xenium, and announced the strategic acquisition of Scale Biosciences to enhance its single-cell analysis platform.
10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025
10x Genomics (NASDAQ: TXG) will release its third-quarter 2025 financial results after the market closes on Wednesday, November 6, 2025. The company will also host a conference call and webcast to discuss these results at 2:00 PM Pacific Time / 5:00 PM Eastern Time on the same day. A replay of the webcast will be available on the 10x Genomics investor website for approximately three months.
